10 Best Cancer Stocks to Invest in for Long-Term Gains

7. MannKind Corporation (NASDAQ:MNKD)

Number of Hedge Fund Holders: 29

Total 5-Year Return: 240.44%

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on innovative inhaled therapies for diseases like diabetes and cancer. In oncology, its lead candidate, MKC1106-MT, targets advanced melanoma using a DNA-based immunotherapy designed to activate T-cells against tumor-specific antigens. The treatment is administered through intranodal injection and has shown promising safety and early clinical response in Phase 1 and ongoing Phase 2 trials for metastatic melanoma.

In Q4 2024, MannKind Corporation (NASDAQ:MNKD) recorded record revenues of $77 million, which is up 31% from the same quarter the year before. Full-year revenues were $286 million, up 43% from the same period the year before. By lowering the principal amount of its debt by $236 million in 2024 and finishing the year with a healthy cash position of $203 million, the company showed excellent financial management. With Q4 revenue of $23 million and full-year revenue of $82 million, the endocrine business unit reported record profits.

Investors are attracted to MannKind Corporation (NASDAQ:MNKD) for its diversified pipeline spanning diabetes, oncology, and orphan lung diseases, with multiple catalysts ahead, including pediatric Afrezza approval and late-stage clinical milestones. The company’s strong financial discipline, evidenced by significant debt reduction and cash reserves, supports its ability to fund growth without dilution.